Mary Kay Goes for Gold in Global Manufacturing Standards March 4, 2026 Quality, Certified: Mary Kay Achieves ISO 22716
All Seas Capital Backs Sereni to Support Buy-and-Build Growth March 4, 2026 Growth strategy focused on consolidating fragmented markets and expanding geographically
Polares Medical Raises $50 Million Series C to Advance U.S. Expansion of MRace Following Strong Clinical Results March 3, 2026 Financing supported by DC Global Ventures, Lumination Capital, existing investors and a new strategic investor
Ada Doubles YoY Growth as Demand for Agentic Customer Service Surges March 3, 2026 Milestones include innovation in Voice channel, global expansion into Europe and APAC, and large enterprise account wins across industries
Real Chemistry Delivers Double-Digit Year-Over-Year Growth in 2025 as Tier-One, Tech-Enabled Healthcare Commercialization Partner March 2, 2026 Company reported $560 million in 2025 revenue, reflecting continued demand for integrated, AI-enabled solutions from molecule to market
Janus Henderson Confirms Receipt of Unsolicited, Non-Binding Proposal February 26, 2026 No Shareholder Action Required at the Time
Telekom Srbija Group Secures Landmark International Credit Ratings from Fitch and Moody’s, Marking Historic First for Western Balkans February 26, 2026 First Western Balkans–headquartered company to secure dual global credit ratings, shining a spotlight on the region’s rising growth and international relevance
Alkermes plc Announces CEO Succession Plan February 25, 2026 — Richard Pops to Retire from Role of Chief Executive Officer Following Distinguished 35-year Career with Alkermes — — Board of Directors Appointed Blair Jackson, Alkermes’ Current Executive Vice President, Chief Operating Officer, as CEO Effective as of August 1, 2026 — — Richard Pops to Continue to Serve as Chairman of the Alkermes Board of Directors —
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026 February 25, 2026 Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2025 and provided financial expectations for 2026. To view the detailed fourth quarter and full year 2025 earnings press release and presentation please visit the company’s investor relations website at https://investor.alkermes.com. Alkermes will host a conference call and webcast [...]
Almirall’s 2025 Results February 23, 2026 Almirall meets guidance for 2025, delivering 12.4% net sales growth and further pipeline progress, continuing its sustained growth trajectory with strong dermatology performance and commercial execution in Europe Almirall delivered net sales growth in 2025 of 12.4% exceeding €1bn (total of €1,108.1MM), revenue increase of 12.5% (total of €1,114.5 MM), and EBITDA growth of 20.9% (total of €232.9 MM) – in line with its guidance and its sustained growth trajectory. This revenue growth further advances Almirall’s leadership in medical dermatology driven by the strong performance of its European dermatology business (+25.6% YoY increase to a total of €608 MM). The continued strong performance of the biologics portfolio is the backbone of Almirall’s growth, with Ilumetri® net sales increasing 12.3% YoY (total of €234.4 MM), and Ebglyss® net sales increasing more than 3x YoY to a total of €110.8 MM – reflecting its strong position and growth trajectory across Europe in the second year after launch. Continued solid performance of the broad dermatology product portfolio with Wynzora® growing 30.5% YoY to a total of €33.8 MM, and Klisyri® growing 33.9% YoY to a total of €32.8 MM, further enhances Almirall’s position as trusted partner for patients and dermatologists. Almirall’s business performance fuels the advancement of a diversified and innovative R&D pipeline addressing skin diseases with high unmet need. Pipeline progress in 2025 included the start of the phase II study of the anti-IL-1RAP mAb in Hidradenitis suppurativa, the start of the phase II study of the IL-2muFc in Alopecia areata, and the approval of Jublia® in Germany and Seysara® in China. Guidance for 2026: net sales growth of 9%-12% and total EBITDA between €270 MM and €290 MM.